Bengaluru-based Peptris Technologies has unveiled a significant milestone in the realm of AI-driven drug discovery by securing $1 million in pre-seed round investment led by Speciale Invest. This funding marks a watershed moment for Peptris as it aims to spearhead advancements in AI-powered solutions within the drug development sector, particularly targeting therapies for undruggable targets in oncology, inflammation, and rare diseases.

The infusion of financial support is poised to catapult Peptris towards accelerating its AI-powered discovery programs and broadening its spectrum of potential drug candidates. By harnessing the cutting-edge capabilities of AI technology, Peptris endeavors to revolutionize the conventional drug discovery landscape, enhancing efficiency and cost-effectiveness in the process.

Peptris’s AI platform is strategically designed to expedite timelines and streamline costs associated with drug discovery. The technology functions by swiftly navigating extensive chemical libraries, swiftly identifying the most promising drug candidates, effectively surmounting the constraints of traditional methodologies.

Sitting at the crossroads of technology and pharmaceutical expertise, Peptris aims to leverage recent AI breakthroughs to fortify its proprietary drug discovery platform. Notably, advancements in unsupervised learning coupled with the availability of expansive chemical libraries have carved a new trajectory in the sector, presenting significant market opportunities. Peptris intends to capitalize on these advancements, driving the development of its proprietary AI platform to truncate preclinical development timelines and associated costs.

In an expanded research landscape, Peptris has broadened its focus to encompass rare diseases, augmenting its existing pursuits in oncology and inflammation. This strategic funding and extended scope align with Peptris’ core mission of harnessing AI to expedite the discovery of novel therapeutic avenues. With a keen emphasis on rare diseases, the company aims to confront over 7,000 known conditions currently devoid of approved treatments, offering a glimmer of hope to affected patients and families.

Established in 2019, Peptris is steered by a founding team amalgamating expertise from pharmaceuticals and computational fields. Led by Narayanan Venkatasubramanian, Anand Budni, Amit Mahajan, and Shridhar Narayanan, the team’s diverse backgrounds reinforce Peptris’ interdisciplinary approach.

Narayanan Venkatasubramanian, CEO and co-founder of Peptris, expressed immense enthusiasm about Speciale Invest’s investment, foreseeing its pivotal role in accelerating AI-powered programs and bolstering the pipeline of potential drug candidates.

Vishesh Rajaram, Managing Partner at Speciale Invest, emphasized the strong synergy between Peptris’ AI-driven initiatives and Speciale’s commitment to supporting deep tech startups revolutionizing industries through scientific research and innovative technologies.